Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Drug Dependence01:17

Drug Dependence

Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychometric properties of the Treatment Effectiveness Assessment in methamphetamine use disorder.

Journal of substance use and addiction treatment·2023
Same author

Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings.

Journal of addiction medicine·2022
Same author

Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene.

European journal of clinical pharmacology·2022
Same author

Bupropion and Naltrexone in Methamphetamine Use Disorder.

The New England journal of medicine·2021
Same author

Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose.

Pain medicine (Malden, Mass.)·2020
Same author

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study.

Journal of addiction medicine·2020
Same journal

An overview of the safety and efficacy of sphenopalatine ganglion stimulation for the treatment of chronic cluster headache.

Expert review of neurotherapeutics·2026
Same journal

Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.

Expert review of neurotherapeutics·2026
Same journal

Remote deep brain stimulation programming in childhood dystonia: opportunities, challenges, and future directions.

Expert review of neurotherapeutics·2026
Same journal

The differential diagnosis of astrocytic neoplasms and its impact on treatment and prognosis.

Expert review of neurotherapeutics·2026
Same journal

Corticosteroids in withdrawal therapy following medication-overuse headache: a systematic review.

Expert review of neurotherapeutics·2026
Same journal

Clinical efficacy of lacosamide in neuropathic pain: a systematic review of randomized controlled trials.

Expert review of neurotherapeutics·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

Buprenorphine for opioid dependence.

Walter Ling1

  • 1Integrated Substance Abuse Programs (ISAP), University of California at Los Angeles, CA, USA. lwalter@ucla.edu

Expert Review of Neurotherapeutics
|May 1, 2009
PubMed
Summary
This summary is machine-generated.

Buprenorphine, an opioid dependence treatment, offers rapid dosage adjustment and low abuse potential, especially with naloxone (Suboxone). While effective, vigilant patient management is still crucial for this medication.

More Related Videos

Optimization of the Longa Middle Cerebral Artery Occlusion Method for Complete Reperfusion
13:18

Optimization of the Longa Middle Cerebral Artery Occlusion Method for Complete Reperfusion

Published on: November 22, 2024

A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat
13:27

A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat

Published on: October 6, 2018

Related Experiment Videos

Last Updated: Jun 23, 2026

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

Optimization of the Longa Middle Cerebral Artery Occlusion Method for Complete Reperfusion
13:18

Optimization of the Longa Middle Cerebral Artery Occlusion Method for Complete Reperfusion

Published on: November 22, 2024

A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat
13:27

A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat

Published on: October 6, 2018

Area of Science:

  • Pharmacology
  • Addiction Medicine

Background:

  • Opioid dependence presents a significant public health challenge.
  • Effective pharmacotherapies are essential for managing opioid use disorder.
  • Buprenorphine represents a key advancement in medication-assisted treatment.

Observation:

  • Buprenorphine offers a favorable safety profile compared to other treatments like methadone.
  • The combination product (buprenorphine/naloxone, Suboxone) demonstrates reduced abuse liability.
  • Physicians can now offer effective opioid-based treatment for opioid dependence.

Findings:

  • Buprenorphine allows for rapid dosage adjustments with minimal severe consequences.
  • Its intrinsic safety and lower abuse potential enhance regulatory and physician acceptance.
  • Buprenorphine provides a vital treatment option, restoring physician capacity to treat opioid dependence.

Implications:

  • Buprenorphine's unique properties position it as a nearly ideal medication for opioid dependence.
  • Clinician vigilance is necessary to manage potential misuse, despite its advantages.
  • Wider acceptance hinges on recognizing buprenorphine's benefits while ensuring responsible patient management.